Evaluation of the Use of Compressive Stockings Impregnated With Hesperetin-Based Nanocapsules in the Healing of Venous Ulcers: A Case Report

Paula dos Passos Menezes1, Cristiane Vilaça Campos Gomes2, Yasmim Maria Barbosa Gomes de Carvalho1, Nayara Gomes Lima Santos1, Valléria Matos Andrade1, Ana Maria Santos Oliveira1, Cláudio Moreira de Lima1 and Adriano Antunes de Souza Araújo1

1Department of Pharmacy, Federal University of Sergipe, São Cristóvão, Brazil. 2Department of Medicine, Federal University of Sergipe, São Cristóvão, Brazil.

ABSTRACT: Venous ulcers are a more severe complication of chronic venous insufficiency, significantly compromising patient quality of life (QoL). Compressive stockings are still the gold standard treatment method with alternative therapies currently being evaluated. In this perspective, we investigate the influence of compressive stockings impregnated with hesperetin-based nanocapsules in the healing process of venous ulcers. Compressive stockings impregnated with hesperetin-based nanocapsules were applied to a consenting patient for 6 months following all relevant ethical principles for patient studies. The patient was evaluated at baseline (T0), 3 months (T3), and 6 months (T6), using photographic register (healing) probes to measure skin melanin, erythema and hydration parameters, and venous diameters, followed by questionnaires regarding QoL and pain perception. Healing was observed at the 3-month time point and with 91.6% and 93.1% of retraction area in larger ulcers of the right leg and lateral portion of the left leg, respectively. The deepest ulcer in a medial portion of the left leg healed 47.3%. A reduction of all measured skin parameters was observed, indicating a possible hesperetin effect. The scores of QoL and pain were, respectively, in the ranges of 91.6 to 31.2 and 7 to 0. Reduction in venous diameters also indicates healing function. These preliminary findings suggest that compressive stockings impregnated with hesperetin nanocapsules enhance venous ulcer healing. Further clinical trial controlled by placebo, involving a greater number of patients, is required to confirm the findings of this case report.

KEYWORDS: Compression, nanotechnology, stockings, varicose ulcer, venous insufficiency

Introduction

Chronic venous insufficiency (CVI) is a debilitating and highly prevalent clinical condition that affects millions of individuals mainly in western countries.1,2 This condition is attributed to several factors such as genetic predisposition and imbalance of protein synthesis (collagen type I and type III), caused by matrix metalloproteinases (MMPs), leading to an abnormal remodeling and distensibility of the veins associated with reduced elasticity.3 Thus, the disease manifests with a variety of signs and symptoms that are caused by valve incompetence or reflux.4 The CVI can result in varicose veins, edema, eczema, lipodermatosclerosis, or venous ulceration, the most advanced clinical manifestation of the disease, which is strongly associated with reflux.5 Most hospital admissions in the United States are due to venous ulcers, occurring in approximately 20,550 patients each year, which generate a treatment cost of US$3 billion/year.6 The first-choice clinical treatment of CVI is worldwide recognized as a compression stocking consisting of initial external pressures of 20 to 30 mm Hg.7 Noteworthy, studies have shown the positive effect of flavonoids (as a micronized purified flavonoid fraction (MPFF)—association of diosmin and hesperidin) on ulcer healing.8 These therapeutic alternatives have been prescribed isolated, demonstrating low oral bioavailability and side effects including gastric disorders.9 In light of these considerations, our research group has recently published a new and efficient method to impregnate hesperetin-based nanocapsules in textile and fiber for compression stocking fabrication. Our results clearly demonstrated the controlled drug release with subsequent permeation/penetration of these nanocapsules from textile to dermis while maintaining particles adhered to the textile during several washes.10 This novel technology may be an excellent topical delivery route, with promising applications in the treatment of venous ulcers. Hesperetin is a natural product derived from hesperidin, a safe flavonoid that is commercially available, with antioxidant, anti-inflammatory, and vasoprotective properties already reported in the scientific literature, and shows promise in maintaining vascular health.11 To understand the role of hesperetin in the ulcer healing process, we performed docking investigations between this drug and vascular endothelial...
growth factor receptor 2 (VEGFR-2), a receptor involved in the pathology of CVI (unpublished data). Noteworthily, hesperetin (−51 kcal/mol) is theoretically able to bind with the receptor VEGFR-2, which is usually cleaved by MMPs in CVI, restoring the endothelial viability12 (Figure 1). The drug interacts with the receptor preventing its degradation by MMPs and could contribute in the healing process. Therefore, this study reports the results of a patient with recurrent and unhealed ulcers of large extension, in which these innovative compression stockings are applied to simultaneously improve quality of life (QoL) and better understand the efficacy of this technology on venous ulcer healing.

**Case Report**

The patient (EGJ; GTP8_747231) was a 50-year-old man with a body mass index (BMI) of 34.1 and with symmetric unhealed venous ulcers in both legs, since 2014. The patient was evaluated by a vascular clinician in the Vascular Surgery Ambulatory of the School Hospital from Federal University of Sergipe, Brazil. The patient was previously treated with Unna boot, *Melilotus officinalis* L., and benzathine benzylpenicillin (6 months prior to the therapy described in this study), without any success. He then received and accepted (by consent form) the proposal to participate in this study (which was approved by the Ethics Committee on Human Research of the Federal University of Sergipe: CAAE—91428318.7.0000.5546, registered at Brazilian Register of Clinical Trials: RBR-5n9cmf under Universal Trial No. U1111-1217-7510). During the protocol, the patient used compressive stockings (3/4, 20-30 mm Hg) impregnated with hesperetin nanocapsules for 6 months (from January to June 2017), on top of wound dressings (without any pharmacologic agent), daily after waking up. Also, the patient washed his compressive stockings at least 5 times per month, due to the adhesive properties of this current technology.10 Every month, we replaced his compressive stockings with other re-impregnated pairs.

This aim of this study was to quantitatively and qualitatively understand improvements in the patient QoL and to report any benefit on ulcer healing during the treatment. To achieve this, the patient answered the Aberdeen Varicose Vein Questionnaire (AVVQ) and Visual Analog Scale (VAS), to determine QoL and pain perception, respectively, at baseline (T0), 3 months (T3), and 6 months (T6) of patient use of experimental compressive stockings. Then, his legs were evaluated through macroscopic register (Nikon D3400 digital camera). These pictures were processed on ImageJ software to measure the healing percentage through the retraction index of the lesion (centimeters), according to equation (1)

\[
\text{Healing} = \left(\frac{T0 - T6}{T0}\right) \times 100
\]

where Healing represents the retraction of the lesion (centimeters), T0 represents day 0, and T6 represents 6 months.

Skin parameters in the periulcer area were measured by Mexameter MX 18 (index of melanin and erythema) and Sebumeter SM 81 (hydration-sebum) (Courage and Khazaka, Cologne, Germany) probes at time points T0, T3, and T6. In addition, the venous diameters of different segments (arch, proximal, knee, and distal segments) of the great saphenous vein (GSV) were evaluated by duplex ultrasound linear probe (Toshiba Nemio XG) at 10Hz. The examination began with the patient in a supine position where patency was initially tested followed by reflux maneuvers with Valsalva and proximal compressions.

**Results and Discussion**

We investigated a case of improvement in ulcer healing, whereas the patient was submitted for new therapy using compressive stockings impregnated with nanocapsules of hesperetin. Macroscopically, the healing process was observable after 3 months of treatment. And 6 months later, we observed a great percentage (92.8%; Figure 2A, and 93.1%; Figure 2C) of lesion area retraction in the superficial ulcers. However, in a deeper ulcer (Figure 2B), the lesion retracted 47.3% after 6 months of treatment.

Skin conditions on periulcer areas such as hyperpigmentation, dehydration, and erythema (Figure 3) are associated with disease’s chronicity and nonhealing.13 The skin pigmentation changes during the course of CVI become more severe as the disease advances. However, this mechanism is not
Figure 2. Macroscopic view of the healing process and quantification of lesion retraction: (A) right leg; (B) left leg medial portion; and (C) left leg lateral portion at time 0 (T0), after 3 months (T3), and after 6 months (T6).
completely elucidated. The abnormality of melanin (dermal and epidermal) metabolism plays an important role in skin dyschromia. In our study, we observed a reduction (Figure 3A) of detectable melanin in the first 3 months of treatment, which coincided with ulcerous healing (Figure 2). This was observed primarily in the right leg, which had less extensive lesions. In general, delayed and nonhealing venous ulcers have a high score of erythema or redness and dehydration due to associated inflammation and infection. We then observed a reduction in erythema (Table 1 and Figure 3B) and an increase in sebum scores (Table 1 and Figure 3C). Tsai et al evaluated the in vivo efficacy of a microemulsion containing hesperetin and reported that the drug could be used as an effective whitening agent due to its antioxidant and anti-inflammatory properties. Together, these results seem to suggest better perfusion and restoration of skin barrier function, typical of the ulcer healing process (Figure 2).

Recent reports have demonstrated the negative impact on QoL for patients with venous ulcers. That variable has a notable personal impact, mainly due to intense pain, compromised sleep, difficulty walking, as well as impaired social and labor activities. The AVVQ was validated in Brazil and has been used as an important instrument to measure the patient-related outcomes specifically for CVI interventions. It is scored from 0 to 100, where 0 means the best QoL and 100 the most severe condition. As can be observed from Figure 4, both AVVQ and VAS, the instruments widely used to measure pain intensity (0–10 scale of pain), agree with the abovementioned results. An improvement was reported the patient’s QoL (AVVQ score: 91.6–31.2) which was directly associated with the decrease of pain (VAS score: 7–0), probably resulting in ulcer healing. Moreover, the patient did not report any gastrointestinal disorder or other adverse events.

Venous Doppler ultrasonography is the gold standard diagnostic modality for evaluation and monitoring response after the therapy of CVI. The venous diameter of different segments from the GSV (superficial vein) observed in our study and shows a reduction (Figure 5) during the healing process. According to previous reports, the normal caliber limit of GSV is 4 mm. Venous reflux in the lower extremities is a manifestation of a degenerative process in the venous wall, typical of this chronic disease. Our findings highlight reflux in the distal portion of superficial veins in both legs, and the reflux was still present in the left leg after 3 months of treatment due to its greater compromised starting state.

In contrast to the Cochrane review, which did not indicate evidence about the ulcer healing with phlebotonics, other studies including systematic reviews and meta-analyses supported effectiveness of MPFF, containing the precursors of hesperetin, in the venous ulcer healing process. Coleridge-Smith et al reported that the oral treatment with MPFF associated to standard compression and wound management accelerates venous leg ulcer healing in larger ulcers (5–10 cm²) of 6–12 month duration. However, there are no studies involving the topical application of these drugs, and the evidence of moderate quality already reported was related to the oral route, where the drug bioavailability is limited by enzymes such as β-glucosidase. Furthermore, hesperetin is recognized by its higher bioavailability compared with other phlebotonics, due to its better membrane interaction. This case report is the first of its kind, giving us an insight

### Table 1. Skin parameters in the periulcer area assessed using Mexameter MX 18, Tewameter TM 300, and Sebumeter SM 815 at time 0 (T0), after 3 months (T3), and after 6 months (T6).

| TIME POINT (MONTHS) | RIGHT LEG | ERYTHEMA (AU) | SEBUM (µG/CM²) | LEFT LEG | ERYTHEMA (AU) | SEBUM (µG/CM²) |
|---------------------|-----------|---------------|----------------|----------|---------------|----------------|
| 0                   | 608       | 345           | 4              | 768      | 517           | 1              |
| 3                   | 324       | 367           | 15             | 529      | 354           | 11             |
| 6                   | 448       | 385           | 0              | 629      | 379           | 0              |

Figure 3. Skin parameters in the periulcer area assessed using Mexameter MX 18 (A, B) and Sebumeter SM 815 (C). The measurements were performed immediately after removing the dressing and cleansing the ulcer and surrounding skin area. All measurements were performed under standard room conditions (25°C, 55% RH), and 3 consecutive readings were taken at the same site. The results are given as mean values. RH indicates relative humidity.
toward understanding the possible association of compression factor, which was already demonstrated in the literature, with the topical effects of hesperetin (vasoprotective, anti-inflammatory, and antioxidant) that could be observed together. These factors may contribute to improving the ulcer healing process, but we still need to deeply investigate the variables involved in this mechanism through robust clinical trials involving a greater number of patients.

Study limitations

This study provides an overall picture of a new method to manage venous ulcers. However, it is limited by the small sample size, which can weaken the power of conclusion.

Conclusions

To the best of our knowledge, this is the first report on a new compressive stocking impregnated with flavonoid-based nanocapsules, which indicated some benefits as an adjuvant for ulcer healing. All the evaluated parameters suggested that hesperetin delivery combined with compression improved the QoL as a possible result of ulcer healing and reduction of venous hypertension. These clinical findings are expected in a successful treatment of the disease. However, there are opportunities for further research to elucidate the biological mechanism of the healing process, the way that the drug is acting (vasoprotective, anti-inflammatory, or antioxidant) and small molecules are involved in this process. Our research group is still working on a clinical trial involving a larger number of patients to answer these questions.

Acknowledgements

The authors thank Sigvaris-Brazil for donation of compression stockings. They also thank Prof Paulo Cesar de Lima Nogueira for the use of the rotaevaporator to obtain the nanocapsules and Prof Luciana Scotti for help on the docking analysis. In addition, they are grateful to Anthony Tahayeri for reviewing the paper for English language.

Author Contributions

PdPM conceived the idea, took the images, and wrote the paper. CVCG performed the clinical evaluation and conducted venous Doppler ultrasonography. YMBGdC impregnated the compressive stockings. NGLS and AMSO evaluated the skin.
parameters. VMA applied the questionnaires. CMDL and AAdSA reviewed the paper.

Informed Consent
The patient was informed about this research protocol and provided written consent to publish this case study.

ORCID ID
Paula dos Passos Menezes https://orcid.org/0000-0002-4908-540X

REFERENCES
1. Raffetto JD. Pathophysiology of chronic venous disease and venous ulcers. Surg Clin North Am. 2018;98:337–347.
2. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15:175–184.
3. Sansivieri-Morel P, Rapin A, Jullien ND, et al. Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res. 2005;42:388–398.
4. Garcia R, Labropoulos N. Duplex ultrasound for the diagnosis of acute and chronic venous diseases. Surg Clin North Am. 2018;98:201–218.
5. Darvall KA, Bate GR, Adam DJ, Bradbury AW. Generic health-related quality of life is significantly worse in varicose vein patients with lower limb symptoms independent of CEAP clinical grade. Eur J Vasc Endovasc Surg. 2012;44:341–344.
6. McArdle M, Hernandez-Vila EA. Management of chronic venous disease. Texas Heart Inst J. 2017;44:347–349.
7. Mallick R, Raju A, Campbell C, et al. Treatment patterns and outcomes in patients with varicose veins. Am Health Drug Benefits. 2016;9:455–465.
8. Franks PJ, Barker J, Collier M, et al. Management of patients with venous leg ulcers: challenges and current best practice. J Wound Care. 2016;25:S1–S67.
9. Dhukhanin AS, Verkin AL. Pleiotropic effects of phlebotropic drugs: from pharmacological advantages to adverse drug interaction. Angiol Sosud Khir. 2017;23:72–80.
10. Menezes PD, Frank LA, Lima BD, et al. Hesperetin-loaded lipid-core nanoparticles in polyamide: a new textile formulation for topical drug delivery. Int J Nanomedicine. 2017;12:2069–2079.
11. Testa L, Calderone V. Nutraceutical value of citrus flavanones and their implications in cardiovascular disease. Nutrients. 2017;9:502.
12. Pocock ES, Alsaigh T, Mazor R, Schmid-Schönbein GW. Cellular and molecular basis of venous insufficiency. Vasu Cell. 2014;6:24.
13. Koh JMC, McKenzie G, McGuiness W. The relationship between periwound skin condition and venous leg ulcer chronicity. Wound Pract Res. 2015;23:82–89.
14. Caggiari A, Rosi C, Francescini M, Innocenti D. The nature of skin pigmentation in chronic venous insufficiency: a preliminary report. Eur J Vasc Endovasc Surg. 2008;35:111–118.
15. Tsai YH, Lee KF, Huang YB, Huang CT, Wu PC. In vitro permeation and in vivo whitening effect of topical hesperetin microemulsion delivery system. Int J Pharm. 2010;388:257–262.
16. Lee DH, Seo ES, Hong JT, et al. The efficacy and safety of a proposed herbal moisturising cream for dry skin and itch relief: a randomised, double-blind, placebo-controlled trial—study protocol. BMC Complement Altern Med. 2013;13:330.
17. Jull A, Muchoney S, Parag V, Wadhman A, Bullen C, Waters J. Impact of venous leg ulceration on health-related quality of life: a synthesis of data from randomised controlled trials compared to population norms. Wound Repair Regen. 2018;26:206–212.
18. Illescas-Montes R, Atkinson RA, Cullum N. Low-level light therapy for treating venous leg ulcers. Cochrane Database Syst Rev. 2018;2018:CD013061.
19. Staniszewska A, Tamba-Raya A, Afolabi E, Bachoo P, Britenden J. The Aberdeen Varicose Vein Questionnaire, patient factors and referral for treatment. Eur J Vasc Endovasc Surg. 2013;46:715–718.
20. Garrant AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK, Krukowski ZH. Towards measurement of outcome for patients with varicose veins. Qual Health Care. 1993;2:5–10.
21. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermitent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63:S240–S252.
22. O’Meara S, Cullum N, Nelson EA, Dunville JC. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012;11:CD000265.
23. Cheung MEFM. Duplex Ultrasound. Treasure Island, FL: StatPearls; 2018.
24. Balyan V, Tajmir S, Hedgire SS, Ganguli S, Prabhakar AM. Lower extremity venous reflux: Cardiace Diag Ther. 2016;6:533–543.
25. Gibson K, Meissner M, Wright D. Great saphenous vein diameter does not correlate with worsening quality of life scores in patients with great saphenous vein incompetence. J Vasc Surg. 2012;56:1634–1641.
26. Martinez-Zapata MJ, Vernooij RW, Ursone Tuuma SM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4:CD003229.
27. Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: the role of Micronized Purified Flavonoid Fraction (MPFF). Phlebology. 2017;32:3–19.
28. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198–208.
29. Londono-Londono J, Lima VR, Jaramillo C, Creczynski-Pasa T. Hesperidin and hesperetin membrane interaction: understanding the role of 7-O-glycoside moiety in flavonoids. Arch Biochem Biophys. 2010;499:6–16.